What Are The Best Long Term Investment Stocks Today?

Apple Inc. (AAPL) stock: A Technological Powerhouse

Apple has made significant strides in artificial intelligence (AI) technology. The introduction of the aptly named Apple Intelligence has garnered considerable attention, with the market reacting positively to the news. Despite some initial skepticism, there’s a growing belief that Apple’s AI initiatives could substantially boost its sales, particularly in China.

iPhone Sales in China

iPhone sales in China have shown signs of recovery, with reports indicating a 52% year-over-year increase in sales of foreign-made smartphones. Although Apple faces fierce competition from local brands, its strategic price cuts have proven effective. Domestically, the release of Apple Intelligence could be the catalyst needed to revitalize the company’s performance.

Diversified Revenue Streams

Apple’s revenue isn’t solely dependent on iPhone and MacBook sales. The company’s services, including the App Store, iCloud, and Apple TV, have seen impressive growth. In Q2 of the 2024 fiscal year, services revenue reached a record $23.8 billion, making up a substantial portion of the company’s total earnings. This segment’s continued expansion is crucial for Apple’s future growth.

Chevron Corporation (CVX) stock: A Dividend Investor’s Dream

Chevron, a leading industry player in the Dow Jones, is highly attractive to investors due to its solid dividend yield of 4.2% and a 37-year streak of increasing dividends. For those seeking substantial passive income, Chevron’s dividends are a reliable source, backed by a robust asset portfolio.

Strong Asset Portfolio

Chevron’s commitment to long-term growth is evident through its ambitious plans in the Permian Basin. Between 2023 and 2027, the company aims to develop 2,200 wells, with plans to expand to over 6,600 wells by 2040. This strategic focus ensures a stable dividend flow for investors.

Positive Cash Flow Outlook

Chevron’s management is optimistic about its free cash flow growth, projecting an average annual increase of over $10 billion by 2027. Currently trading at a price-to-cash-flow ratio of 7.7, which is below the five-year average of 8.3, Chevron presents a timely opportunity for dividend-focused investors.

Eli Lilly and Company (LLY) stock: Leading in Innovative Healthcare

Eli Lilly's lebrikizumab study results presentation at the American Academy of Dermatology

Eli Lilly boasts a market capitalization exceeding $800 billion and a diverse product lineup, including groundbreaking new medications. The company’s focus areas—diabetes, neurology, oncology, and immunology—are rapidly growing and hold significant commercial potential.

New Drugs Driving Revenue

Eli Lilly’s development of tirzepatide (marketed as Mounjaro for type II diabetes and Zepbound for obesity) has been a game-changer. These drugs have quickly become key players in Lilly’s portfolio, with demand surging since their respective launches in 2022 and 2023. Analysts predict that tirzepatide could reach peak sales of approximately $25 billion.

Expanding Product Line

In 2023, Eli Lilly received approvals for several other drugs, including Omvoh for ulcerative colitis and Jaypirca, a BTK inhibitor for mantle cell lymphoma and chronic lymphocytic leukemia. The upcoming donanemab for early-stage Alzheimer’s disease, pending FDA approval, could further enhance Lilly’s market position and revenue growth.

Interested in more detailed stock picks and investment strategies? Check out our selection of the best stocks in the market right now. Access our premium stock picks here.